phrykt

InspireMD, Inc. (NSPR): who owns it and who trades it

As of Nov 16, 2026, NSPR insiders reported 12 open-market sales worth $127K and 15 purchases worth $408K in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Shane Thomas Gleason (Chief Commercial Officer), with $127K. 3 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling InspireMD

From the latest filings

Overall: about as much buying as selling. Famous investors mostly sold. Funds mostly bought. Insiders was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns NSPR

36 funds and institutions reported NSPR shares worth $17.4M at the end of Q2 2026, about 53% of the company. The largest holder is Nantahala Capital Management, LLC with 14.4%.

Funds and institutions (13F) 53%Everyone else 47%

10 largest owners, by share of the company

Nantahala Capital Management, LLC14.4%
Rosalind Advisors, Inc.8.3%
Aberdeen Group plc7.9%
Orbimed Advisors LLC6.7%
Parkman Healthcare Partners LLC5.2%
Marshall Wace, LLP4.0%
Soleus Capital Management, L.P.2.2%
Pura Vida Investments, LLC1.0%
Ingalls & Snyder LLC0.8%
Affiance Financial, LLC0.5%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Nantahala Capital Management, LLC6.75M14.43%$4.7M+100%
Rosalind Advisors, Inc.3.91M8.35%$2.7MNo change
Aberdeen Group plc3.70M7.90%$2.6M+17%
Orbimed Advisors LLC3.13M6.70%$2.2MNo change
Parkman Healthcare Partners LLC2.42M5.16%$1.7MNo change
Marshall Wace, LLP1.86M3.98%$1.3MNo change
Soleus Capital Management, L.P.1.05M2.23%$732KNo change
Pura Vida Investments, LLC450,5170.96%$315KNo change
Ingalls & Snyder LLC368,8000.79%$258K-3%
Affiance Financial, LLC250,3700.53%$175KNo change
Velan Capital Investment Management LP148,1380.32%$104K-93%
BlackRock, Inc.122,9930.26%$86.1K+53%
Renaissance Technologies LLC112,8320.24%$79K+541%
Creative Planning108,9640.23%$76.3K+453%
Schonfeld Strategic Advisors LLC99,2750.21%$69.5KNew
Hrt Financial LP59,7540.13%$41KNew
XTX Topco Ltd49,0290.10%$34.3K+297%
Centiva Capital, LP44,1230.09%$30.9K+78%
Cambridge Investment Research Advisors, Inc.40,3320.09%$28KNew
Millennium Management LLC37,6770.08%$26.4K-66%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, NSPR insiders reported $408K of open-market purchases and $127K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$408K
15 trades, 4 people
Sales, 12 months
$127K
12 trades, 1 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
May 27, 2026
Filed May 29, 2026

Purchases and sales by month

$366K$366KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
May 27, 2026Paul StukaDirectorPurchase20,000$0.88$17.6KForm 4
May 19, 2026Shane Thomas GleasonChief Commercial OfficerSale22,778$1.01$23KForm 4
May 14, 2026Paul StukaDirectorPurchase5,000$1.15$5.8KForm 4
May 13, 2026Paul StukaDirectorPurchase10,000$1.16$11.6KForm 4
May 12, 2026Marvin SlosmanCEOPurchase21,000$1.20$25.2KForm 4
May 11, 2026Paul StukaDirectorPurchase10,000$1.19$11.9KForm 4
May 8, 2026Paul StukaDirectorPurchase65,626$1.16$76.1KForm 4
May 7, 2026Scott R. WardDirectorPurchase73,255$1.15$84.2KForm 4
May 7, 2026Paul StukaDirectorPurchase6,378$1.15$7.3KForm 4
May 7, 2026Gary S RoubinDirectorPurchase90,000$1.18$106KForm 4
May 6, 2026Scott R. WardDirectorPurchase15,995$1.15$18.4KForm 4
May 6, 2026Paul StukaDirectorPurchase1,517$1.12$1.7KForm 4
Feb 2, 2026Shane Thomas GleasonChief Commercial OfficerSale2,941$1.59$4.7KForm 4
Feb 2, 2026Shane Thomas GleasonChief Commercial OfficerSale2,000$1.60$3.2KForm 4
Jan 30, 2026Shane Thomas GleasonChief Commercial OfficerSale2,900$1.63$4.7KForm 4
Jan 29, 2026Shane Thomas GleasonChief Commercial OfficerSale5,000$1.65$8.2KForm 4
Jan 28, 2026Shane Thomas GleasonChief Commercial OfficerSale12,395$1.65$20.5KForm 4
Jan 27, 2026Shane Thomas GleasonChief Commercial OfficerSale4,781$1.66$7.9KForm 4
Jan 22, 2026Shane Thomas GleasonChief Commercial OfficerSale8,411$1.57$13.2KForm 4
Jan 21, 2026Shane Thomas GleasonChief Commercial OfficerSale17,593$1.62$28.5KForm 4
Jan 20, 2026Shane Thomas GleasonChief Commercial OfficerSale2,955$1.59$4.7KForm 4
Jan 16, 2026Shane Thomas GleasonChief Commercial OfficerSale2,250$1.61$3.6KForm 4
Jan 15, 2026Shane Thomas GleasonChief Commercial OfficerSale2,909$1.58$4.6KForm 4
Dec 9, 2025Paul StukaDirectorPurchase2,710$1.81$4.9KForm 4
Dec 9, 2025Paul StukaDirectorPurchase5,073$1.81$9.2KForm 4
Dec 5, 2025Paul StukaDirectorPurchase5,073$1.86$9.4KForm 4
Dec 4, 2025Paul StukaDirectorPurchase10,130$1.85$18.7KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Paul StukaDirector$174K–May 27, 2026
Shane Thomas GleasonChief Commercial Officer–$127KMay 19, 2026
Gary S RoubinDirector$106K–May 7, 2026
Scott R. WardDirector$103K–May 7, 2026
Marvin SlosmanCEO and President, Director$25.2K–May 12, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

NSPR short interest

Low short interest. 0.5% of NSPR shares are sold short: about 1 share in 185. Over the last 12 reports the number of shares short went up 616%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 251,530 NSPR shares were sold short, 0.5% of the shares outstanding, up 210.9% from the report before. At the average daily volume of 329,636 shares, buying them all back would take about 1.0 trading days (days to cover).

Shares short, % of all shares

0.54%May 15Oct 300.62%

Days to cover

1.0May 15Oct 302.7

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 2026251,5300.54%+211%329,6361.0
Oct 15, 202680,9000.17%+260%150,4071.0
Sep 30, 202622,4660.05%-11%70,5481.0
Sep 15, 202625,3640.05%-35%41,4191.0
Aug 31, 202638,8790.08%-54%106,5851.0
Aug 14, 202685,3360.18%-2%102,9801.0
Jul 31, 202687,2810.19%+14%34,7102.5
Jul 15, 202676,8730.16%+3%85,5961.0
Jun 30, 202674,4650.16%+42%88,8021.0
Jun 15, 202652,5950.11%+192%186,3391.0
May 29, 202618,0040.04%-49%197,0891.0
May 15, 202635,1220.08%-16%1.23M1.0

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

InspireMD company events

InspireMD filed 14 reports on Form 8-K in the last 12 months, 6 of them about an important change (leadership, listing). The latest was on Sep 21, 2026.

  1. Sep 21, 2026AgreementInspireMD, Inc. entered into amendments with certain of the holders of the Company’s existing warrants to purchase common stock, par value $0.0001 per share, consisting of (i) Series J warrants to purchase up to 9,543,952 shares of Common Stock and (ii) Series K warrants to purchase up to 9,543,947… Filing
  2. Aug 17, 2026ResultsReleased financial results. Filing
  3. Jul 29, 2026LeadershipInspireMD, Inc. provided notice to Shane Gleason, the Company’s Chief Commercial Officer, that his position has been eliminated. Filing
  4. Jul 23, 2026ListingInspireMD, Inc. received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that it is not in compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2), which… Filing
  5. Jul 2, 2026LeadershipMr. Raymond W. Cohen, a Class III member of the board of directors of InspireMD, Inc., a member of the Audit Committee of the Board and a member of the Compensation Committee of the Board, tendered his resignation from the Board, effective July 1, 2026. Filing
  6. Jun 11, 2026AnnouncementShared information with investors. Filing
  7. Jun 3, 2026VoteReported shareholder vote results. Filing
  8. May 22, 2026LeadershipMr. Paul Stuka notified InspireMD, Inc. of his decision to not seek reelection as a Class I director of the Board of Directors of the Company at the Company’s 2027 Annual Meeting of Stockholders and to retire from the Board. Filing
  9. May 4, 2026ResultsReleased financial results. Filing
  10. May 1, 2026AnnouncementOf this Current Report on Form 8-K. Filing
  11. Apr 3, 2026AgreementInspireMD, Inc. entered into an Equity Distribution Agreement with BTIG, LLC, as sales agent, pursuant to which the Company may offer and sell, from time to time, at its option, through or to BTIG shares of the Company’s common stock, $0.0001 par value per share. Filing
  12. Mar 18, 2026ResultsReleased financial results. Filing
  13. Mar 4, 2026LeadershipInspireMD, Inc. provided a notice of dismissal to Andrea Tommasoli, the Company’s Chief Operating Officer. Filing
  14. Dec 19, 2025LeadershipKathryn Arnold, a Class III member of the board of directors of InspireMD, Inc. (the “Board” and the “Company”, respectively), a member of the compensation committee of the Board, the nominating and corporate governance committee of the Board and the research and development committee of the Board… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

InspireMD financials

Famous investors that hold NSPR

3 of the 50 well-known investors we track reported holding NSPR in their latest 13F filing. The largest position is Jim Simons's, worth $58.7K.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Jim Simons · Renaissance TechnologiesQ3 202687,892$58.7K0.0%-22%
Israel Englander · Millennium ManagementQ3 202621,760$14.6K0.0%-42%
Ken Griffin · Citadel AdvisorsQ3 202618,916$12.7K0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about InspireMD, Inc. (NSPR) stock

Who owns the most NSPR stock?

The largest reported owner of InspireMD, Inc. (NSPR) is Nantahala Capital Management, LLC, with 14.4% of the company. In total, 36 funds and institutions reported holding NSPR at the end of Q2 2026, together about 53% of the shares. See the largest owners.

Are NSPR insiders buying or selling?

In the last 12 months, NSPR insiders reported 15 open-market purchases worth $408K and 12 sales worth $127K. The latest trade was on May 27, 2026. See every trade.

What is the short interest in NSPR?

As of Oct 30, 2026, 251,530 NSPR shares were sold short, 0.5% of the shares outstanding, up 210.9% from the report before. At the average daily volume of 329,636 shares, buying them all back would take about 1.0 trading days (days to cover). See the history.

Which famous investors hold NSPR?

3 of the 50 well-known investors we track reported NSPR in their latest 13F filing, including Jim Simons, Israel Englander, Ken Griffin. The largest position is worth $58.7K. See all holders.

Executive pay

InspireMD's chief executive was paid a total of $3.1M for the year ended Dec 31, 2025, down 6% from $3.3M the year before. In the last 12 months, InspireMD's executives and directors bought $408K of stock on the open market and sold $289K.

Chief executive, total pay$3.1MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$1.3MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$1.8MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.